Revvity, Inc.

NYSE:RVTY Stock Report

Market Cap: US$14.9b

Revvity Valuation

Is RVTY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVTY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$123.17
Fair Value
3.3% undervalued intrinsic discount
18
Number of Analysts

Below Fair Value: RVTY ($119.16) is trading below our estimate of fair value ($123.17)

Significantly Below Fair Value: RVTY is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVTY?

Key metric: As RVTY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RVTY. This is calculated by dividing RVTY's market cap by their current earnings.
What is RVTY's PE Ratio?
PE Ratio51.2x
EarningsUS$283.07m
Market CapUS$14.89b

Price to Earnings Ratio vs Peers

How does RVTY's PE Ratio compare to its peers?

The above table shows the PE ratio for RVTY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63.6x
AVTR Avantor
47.7x29.0%US$15.0b
QGEN Qiagen
109.7x33.4%US$9.5b
TECH Bio-Techne
75.4x21.9%US$12.0b
ICLR ICON
21.6x11.6%US$16.2b
RVTY Revvity
51.2x20.2%US$14.9b

Price-To-Earnings vs Peers: RVTY is good value based on its Price-To-Earnings Ratio (51.2x) compared to the peer average (63.6x).

Price to Earnings Ratio vs Industry

How does RVTY's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.1xn/aUS$139.80k
No more companies available in this PE range
RVTY 51.2xIndustry Avg. 35.0xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RVTY is expensive based on its Price-To-Earnings Ratio (51.2x) compared to the Global Life Sciences industry average (35.1x).

Price to Earnings Ratio vs Fair Ratio

What is RVTY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVTY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.2x
Fair PE Ratio29.5x

Price-To-Earnings vs Fair Ratio: RVTY is expensive based on its Price-To-Earnings Ratio (51.2x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVTY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$119.16
US$141.19
+18.5%
8.1%US$163.44US$120.00n/a18
Jan ’26US$111.61
US$138.47
+24.1%
8.6%US$163.44US$120.00n/a18
Dec ’25US$116.14
US$138.68
+19.4%
8.2%US$162.17US$120.00n/a18
Nov ’25US$121.04
US$137.90
+13.9%
8.4%US$162.17US$120.00n/a18
Oct ’25US$124.44
US$133.87
+7.6%
7.8%US$162.00US$120.00n/a18
Sep ’25US$122.54
US$133.87
+9.2%
7.8%US$162.00US$120.00n/a18
Aug ’25US$125.03
US$134.10
+7.3%
7.9%US$162.00US$120.00n/a17
Jul ’25US$103.00
US$124.04
+20.4%
9.9%US$162.00US$105.00n/a16
Jun ’25US$109.26
US$123.67
+13.2%
10.3%US$162.00US$105.00n/a16
May ’25US$102.60
US$123.61
+20.5%
10.3%US$162.00US$105.00n/a16
Apr ’25US$103.27
US$123.11
+19.2%
10.6%US$162.00US$100.00n/a16
Mar ’25US$107.12
US$123.11
+14.9%
10.6%US$162.00US$100.00n/a16
Feb ’25US$109.26
US$117.66
+7.7%
15.1%US$162.00US$85.00US$126.1316
Jan ’25US$109.31
US$104.79
-4.1%
16.5%US$162.00US$85.00US$111.6117
Dec ’24US$91.28
US$106.71
+16.9%
17.0%US$162.00US$85.00US$116.1414
Nov ’24US$82.54
US$106.71
+29.3%
17.0%US$162.00US$85.00US$121.0414
Oct ’24US$110.70
US$143.24
+29.4%
9.9%US$170.00US$120.00US$124.4416
Sep ’24US$116.92
US$144.31
+23.4%
9.1%US$170.00US$125.00US$122.5416
Aug ’24US$122.63
US$143.74
+17.2%
9.9%US$170.00US$120.00US$125.0316
Jul ’24US$118.79
US$145.53
+22.5%
11.1%US$170.00US$120.00US$103.0015
Jun ’24US$115.67
US$147.19
+27.3%
11.4%US$170.00US$120.00US$109.2615
May ’24US$130.26
US$155.78
+19.6%
9.1%US$182.00US$134.00US$102.6014
Apr ’24US$133.26
US$158.92
+19.3%
8.0%US$182.00US$140.00US$103.2712
Mar ’24US$123.50
US$158.92
+28.7%
8.0%US$182.00US$140.00US$107.1212
Feb ’24US$139.27
US$160.00
+14.9%
8.3%US$185.00US$140.00US$109.2612
Analyst Price Target
Consensus Narrative from 18 Analysts
US$141.19
Fair Value
15.6% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 08:38
End of Day Share Price 2025/02/06 00:00
Earnings2024/12/29
Annual Earnings2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revvity, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays